Ladenburg initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $15 price target The firm cites the emerging profile of ORIC-944 as “a potential fast-follower to mevrometostat” as well as the strategic pivot for development of ORIC-114 from second-line to the first-line, which represents a larger addressable population and opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals Elects Directors at Annual Meeting
- JPMorgan biotech/pharma analysts hold analyst/industry conference call
- Oric Pharmaceuticals files to sell 19.23M shares of common stock for holders
- Promising Potential of ORIC-944 in mCRPC Treatment Drives Buy Rating and $22 Price Target
- Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz